Those who received the Pfizer-BioNTech, Moderna or J&J vaccines are less likely to die from non-COVID-related causes, a CDC study found.
The decision paves the way for millions more people in the US to get the additional protection with the highly contagious Delta variant of the virus causing breakthrough infections.
The government would not recommend one shot over another, and it might note that using the same vaccine as a booster when possible is preferable, the NYT report said.
New data shows that those who get an mRNA jab after the Johnson & Johnson vaccine will have a stronger antibody response.
FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) panel will hold a meeting on Oct. 14 to discuss a booster dose of Moderna vaccine, and Johnson & Johnson on Oct. 15.
Both J&J's and AstraZeneca vaccines have previously been associated with a very rare combination of blood clotting and low platelet counts known as thrombosis with thrombocytopenia syndrome (TTS).
Johnson & Johnson said a booster given two months after the first dose increased antibody levels four to six-fold.
Two early-stage trials found that a booster dose of Johnson & Johnson's COVID vaccine significantly increased levels of antibodies.
The CDC is not recommending boosters, and advisors to the agency said at a public meeting this week there is not yet significant evidence of declining protection from the vaccines.
The decision comes after European Medicines Agency (EMA) backed the use of the vaccine in 12- to 15-year olds earlier in the day
JPOST Digital Library
